CATEGORY 66 AUSTRALASIAN DENTIST AHPRA compliance remain critical. Only dental practitioners with accredited facial aesthetics training should perform these procedures. At Dermal Distinction Academy, all courses are designed specifically for dentists, staying within scope and aligned with national standards for education, advertising, and patient consent. Looking beyond the label: Safety and long-term considerations Patients today are more informed and expect transparency. They ask about brands, ingredients, and longevity – and practitioners must be prepared to explain their product choices clearly. A “one-size-fits-all” approach can produce inconsistent outcomes. Instead, assess each patient based on: X Muscle mass and strength X Metabolic rate • Treatment frequency X History of prior toxin use X Signs of reduced efficacy If reduced responsiveness occurs, antibody formation should be considered, and a switch to a purified formulation may help restore treatment success. The future of Botulinum Toxin As the field continues to evolve, evidence increasingly suggests that the future of neuromodulator therapy lies in selecting formulations with the lowest risk of antibody formation. Patients are starting treatment earlier and continuing for decades, meaning immunogenicity – the body’s ability to recognise and neutralise the toxin – has become a clinical reality. Formulations containing bacterial flagellin, complexing proteins, or polysorbate compounds act as immunological triggers, stimulating the development of neutralising antibodies that can render the toxin ineffective. Once formed, these antibodies can also compromise future medical treatments such as those for migraine, spasticity, or dystonia. Practitioners should therefore prioritise high-purity, low-immunogenic formulations and incorporate informed consent discussions regarding antibody formation, particularly when using products containing complexing proteins or other immunogenic additives. Failure to obtain such consent may have ethical and legal implications, especially if future medical therapy becomes limited by immunoresistance. The next generation of aesthetic practice will not be defined by duration or diffusion alone, but by purity, safety, and long-term patient outcomes. The modern injector must think beyond immediate results and consider how pharmaceutical choices influence a patient’s treatment success for years to come. Final thoughts Selecting a botulinum toxin is no longer about brand familiarity – it is about clinical reasoning, scientific evidence, and longterm foresight. As dentists, our anatomical precision and focus on patient function give us an exceptional advantage in facial injectables – but that advantage depends on continuing education and a commitment to evidence-based practice. At Dermal Distinction Academy, we teach injectors not just how to use botulinum toxin but why understanding its science matters. By recognising molecular differences, formulation variables, and immunogenic potential, practitioners can deliver predictable, durable, and safe outcomes for every patient. Dermal Distinction Academy holds a secure wholesale licence and can supply account holders with selected pharmaceuticals and consumables for approved treatments. Apply for your product account via our website. X For more information about Botulinum Toxin and product accounts, visit www.dermaldistinction.com Dermal Distinction Academy Education within scope. AHPRA-compliant. Evidence-based. Ph: 03 9851 6771 email: academy@dermaldistinction.com www.dermaldistinction.com CLINICAL õõõŚÖÙË£ÅäŚËÄŚé Developed for High & low speed: Handpieces, Turbines, Airmotors /XEULFDWHV &OHDQV 7HPSHUDWXUH 6WDEOH Proudly Australian Made & Owned
RkJQdWJsaXNoZXIy MTc3NDk3Mw==